APA (7th ed.) Citation

Cairo, M., EdD, J. R. G., Barnes, Y., Drea, E., & Carrol, S. (2022). MDS-065 Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy – Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol. Clinical lymphoma, myeloma and leukemia, 22, S302-S303. https://doi.org/10.1016/S2152-2650(22)01393-3

Chicago Style (17th ed.) Citation

Cairo, Mitchell, Jack R. Gallagher EdD, Yvonne Barnes, Edward Drea, and Susan Carrol. "MDS-065 Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy – Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol." Clinical Lymphoma, Myeloma and Leukemia 22 (2022): S302-S303. https://doi.org/10.1016/S2152-2650(22)01393-3.

MLA (9th ed.) Citation

Cairo, Mitchell, et al. "MDS-065 Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy – Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol." Clinical Lymphoma, Myeloma and Leukemia, vol. 22, 2022, pp. S302-S303, https://doi.org/10.1016/S2152-2650(22)01393-3.